OTC · RSPI
RespireRx Pharmaceuticals Inc.
$0.00$0.00 (0.0%)
RespireRx Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 33.33% below the high.
Loading market information…
OTC · RASP · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Actavia Life Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 87.5% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Actavia Life Sciences, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Actavia Life Sciences, Inc. operates as a biotechnology enterprise specializing in the development of therapeutic solutions aimed at treating various forms of leukemia and lymphoma. Additionally, the company is engaged in formulating small molecule drug candidates, with a particular emphasis on addressing acute myeloid leukemia. Established in 2013, its corporate headquarters are situated in New York, NY.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:54 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.00$0.00 (0.0%)
RespireRx Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 33.33% below the high.
$0.01$0.00 (0.0%)
ChitogenX Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.01$0.00 (0.0%)
Viracta Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.8% below the high.
$0.00$0.00 (0.0%)
Innovation Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.6% below the high.
$0.00$0.00 (0.0%)
MedGen, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Lift & Co. Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Nascent Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.85% below the high.
$0.00$0.00 (0.0%)
Paradigm Medical Industries, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
